We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
+340.85%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$539M
AUM Growth
+$38.3M
Cap. Flow
+$82.7M
Cap. Flow %
15.36%
Top 10 Hldgs %
44.1%
Holding
265
New
51
Increased
68
Reduced
40
Closed
62

Sector Composition

Rank Sector Weight
1 Healthcare 78.09%
2 Financials 3.23%
3 Technology 0.19%
4 Consumer Discretionary 0.05%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ACOG
251
Alpha Cognition
ACOG
$199M
-204,348
Closed -$1.2M
PVLA
252
Palvella Therapeutics
PVLA
$2.27B
-144,641
Closed -$1.74M
ONC
253
BeOne Medicines Ltd
ONC
$39.4B
-2,974
Closed -$549K
AIMAW
254
DELISTED
Aimfinity Investment Corp I Warrant
AIMAW
-18,000
Closed -$126
CMRX
255
DELISTED
Chimerix, Inc.
CMRX
-122,236
Closed -$425K
EDR
256
DELISTED
Endeavor Group Holdings, Inc.
EDR
-210,729
Closed -$6.59M
GLSTW
257
DELISTED
Global Star Acquisition, Inc. Warrants
GLSTW
-120,000
Closed -$3.61K
GLSTR
258
DELISTED
Global Star Acquisition, Inc. Right
GLSTR
-88,560
Closed -$13.3K
FTIIW
259
DELISTED
FutureTech II Acquisition Corp. Warrant
FTIIW
-30,000
Closed -$462
CDMO
260
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
-120,000
Closed -$1.48M
PSTX
261
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
-134,109
Closed -$1.29M

Similar funds

ADAR1 Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, ADAR1 Capital Management held 265 positions worth $539M, up 7.7% from $500M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

ADAR1 Capital Management deployed $82.7M of net new capital in Q1 2025, opening 51 new positions and adding to 68 existing holdings. Its largest new stake was SpringWorks Therapeutics: 207,778 shares worth $9.17M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 78% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was BridgeBio Pharma, an estimated $11.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2025 buy was SpringWorks Therapeutics: 207,778 shares worth $9.17M.
  • ADAR1 Capital Management added most to Keros Therapeutics in Q1 2025, an estimated $17M increase.
  • ADAR1 Capital Management's biggest Q1 2025 reduction was BridgeBio Pharma, cutting an estimated $11.4M.
  • ADAR1 Capital Management fully exited Endeavor Group Holdings, Inc. in Q1 2025, selling an estimated $6.59M.
  • ADAR1 Capital Management's ten largest holdings make up 44% of its $539M portfolio in Q1 2025.
  • ADAR1 Capital Management opened 51 new positions and closed 62 in Q1 2025.
  • ADAR1 Capital Management's portfolio value rose 7.7% quarter-over-quarter to $539M.

Based on ADAR1 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.